Eltrombopag
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Poor Graft Function
Conditions
Poor Graft Function
Trial Timeline
Dec 17, 2018 → Nov 3, 2020
NCT ID
NCT03718533About Eltrombopag
Eltrombopag is a phase 2 stage product being developed by Novartis for Poor Graft Function. The current trial status is terminated. This product is registered under clinical trial identifier NCT03718533. Target conditions include Poor Graft Function.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04837703 | Pre-clinical | Active |
| NCT05286164 | Phase 2 | UNKNOWN |
| NCT03988608 | Phase 2 | Completed |
| NCT03718533 | Phase 2 | Terminated |
| NCT03664518 | Phase 2 | Completed |
| NCT03524612 | Phase 2 | Completed |
| NCT02877212 | Phase 3 | UNKNOWN |
| NCT02323178 | Phase 1/2 | Completed |
| NCT01703169 | Phase 2 | Completed |
| NCT01715779 | Pre-clinical | Completed |
| NCT01416311 | Pre-clinical | Completed |
Competing Products
7 competing products in Poor Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus | Sumitomo Pharma | Approved | 85 |
| Lunesta | Sumitomo Pharma | Approved | 85 |
| Rosuvastatin Calcium | AstraZeneca | Phase 1 | 33 |
| Lutropin alfa + Follitropin alfa | Merck | Approved | 85 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Cabozantinib S-malate | Exelixis | Phase 2 | 49 |